Erick Otieno

Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
  • Wendy's lowers guidance amid revenue decline, but focuses on global expansion and shareholder returns.
  • Federal probe investigates NY AG Letitia James over civil rights violations in high-profile cases against Trump and NRA.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Gilead Sciences reports strong Q2 2025 results, driven by robust HIV drug sales, and raises full-year guidance, making its stock a top performer.
  • Wendy's lowers guidance amid revenue decline, but focuses on global expansion and shareholder returns.
  • Federal probe investigates NY AG Letitia James over civil rights violations in high-profile cases against Trump and NRA.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Erick Otieno